MiR-183-5p Promotes Tumor Progression of Osteosarcoma and Predicts Poor Prognosis in Patients

Cancer Manag Res. 2021 Jan 27:13:805-814. doi: 10.2147/CMAR.S285909. eCollection 2021.

Abstract

Background: Although miRNA-183-5p plays a critical role in many cancer types, including gastric cancer, hepatocellular carcinoma, prostate cancer, renal cell cancer and breast cancer, its role in osteosarcoma remains unclear.

Methods: Expression levels of miR-183-5p were detected in osteosarcoma tissues and cell lines using qRT-PCR. The effect of miR-183-5p on the survival and recurrence of osteosarcoma patients was analyzed in a cohort of 80 patients using Kaplan-Meier curves and Cox regression analysis. Effects of miR-183-5p on cell proliferation, migration and invasion abilities were evaluated using CCK-8, crystal violet and transwell assays.

Results: The expression of miR-183-5p was found to be upregulated in human osteosarcoma tissues and cell lines. Moreover, miR-183-5p expression was observed to be closely associated with tumor size, TNM stage and lung metastasis. Notably, high expression of miR-183-5p was shown to be able to predict unfavorable clinical prognosis in osteosarcoma patients. Additionally, whilst overexpression of miR-183-5p was observed to significantly promote the proliferation, migration and invasion of osteosarcoma cells; an inhibitory effect was observed with knockdown of miR-183-5p.

Conclusion: This study demonstrated that miR-183-5p acts as an oncogene and plays a critical role in the regulation of osteosarcoma tumor progression, and our results suggest a novel potential prognostic and therapeutic value of miR-183-5p in osteosarcoma.

Keywords: biomarker; miR-183-5p; osteosarcoma; prognosis; progression.